Cite this as: Yang YANG, Xiaolin GU, Jingsong HE, Yongxian HU, Zhen CAI. Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy[J]. Journal of Zhejiang University Science B, 2024, 25(8): 719-722. http://doi.org/10.1631/jzus.B2300835

Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy

Key words: Waldenström macroglobulinemia; Chimeric antigen receptor T cell therapy; relapsed and refractory

Research summary

Waldenström macroglobulinemia (WM) is a rare type of neoplasm of small lymphocytes, plasmacytoid lymphocytes, and plasma cells involving bone marrow, and sometimes lymph node and spleen, and often is associated with clonal IgM globulinemia. It is incurable, though usually accompanied by an indolent clinical course.



JZUSB

Research summary

In this article, we reported a challenging WM case. The patient had relapsed and refractory disease with extramedullary involvement after chemotherapy, immunotherapy, and Bruton's tyrosine kinase (BTK) inhibitor therapy, but her condition was improved after CD19-directed CAR-T cell therapy. We also reviewed the reported CAR-T treated WM cases in the literature.



JZUSB

Research summary

The patient in our case has been followed up for over a year and her disease remains in very good partial remission, indicating the potential of CAR-T cell therapy as an alternative for R/R WM. Larger-scale clinical studies are eagerly apticipated to evaluate the efficacy and safety of this therapy.

JZUS-B

